Back to News
Market Impact: 0.15
Fortitude Biomedicines Announces Oral Presentation of FTB-918 for the Treatment of Axial Spondyloarthritis at ACR Convergence 2026
Source: Business Wire
Healthcare & Biotech
Fortitude Biomedicines announced that FTB-918, its treatment candidate for axial spondyloarthritis, will be presented orally at ACR Convergence 2026. The announcement provides no clinical results or other data on the candidate.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
More News
- J&J's 6% slide on an imperfect quarter is a gift to prospective buyers
- UnitedHealth Group tops estimates, hikes profit outlook as insurer manages high medical costs
- J&J beats earnings estimates; Middle East conflict weighs on medical-device sales
- Rhythm Pharmaceuticals launches IMCIVREE in Japan for obesity
- Liquidia (NASDAQ:LQDA) CMO Rajeev Saggar disposes of $262,528 in stock
- Alaunos completes Velaris acquisition, raises $350 million